Author:
Golan Talia,Sella Tal,O'Reilly Eileen M,Katz Matthew H G,Epelbaum Ron,Kelsen David P,Borgida Ayelet,Maynard Hannah,Kindler Hedy,Friedmen Eitan,Javle Milind,Gallinger Steven
Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. NCCN Clinical Practice Guidelines in Oncology–Pancreatic Adenocarcinoma. National Comprehensive Cancer Network. 2016.
2. Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, Peretz T (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505–514.
3. Biankin AV, Maitra A (2015) Subtyping pancreatic cancer. Cancer Cell 28: 411–413.
4. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, De La Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817–1825.
5. Easton DF, Matthews FE, Ford D, Swerdlow AJ, Peto J (1996) Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 65: 284–294.
Cited by
71 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献